Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · SCYNEXIS INC (SCYX)

SCYNEXIS appoints Steven K. Burke, M.D., to its board of directors

Neutral Impact 2 of 5 leadership Written later

SCYNEXIS said its board appointed Steven K. Burke, M.D., as a director effective September 18, 2026, and named him to the Nominating and Corporate Governance Committee. Dr. Burke has more than 30 years of biopharmaceutical experience and most recently served at Akebia Therapeutics as Senior Vice President, Chief Research and Development Officer and Chief Medical Officer. The company says his kidney disease drug development expertise supports its SCY-770 program for ADPKD.

Key points

  • Board appointment effective September 18, 2026; Dr. Burke serves until the 2027 Annual Meeting of Stockholders.
  • Non-employee director pay includes a $45,000 annual retainer and a $5,000 annual retainer for committee service.
  • Initial grants of options and restricted stock units each cover 5,750 shares; the option exercise price is $4.46, the September 18, 2026 closing price.
  • The company issued a press release on September 22, 2026, furnished as Exhibit 99.1.

The filing

CompanySCYNEXIS INC (SCYX)
Form8-K, current report
Filed with the SECSep 22, 2026, 8:05 AM ET
Accession number0001178253-26-000035

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.